Stocktoria

Kalaris Therapeutics, Inc. KLRS

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-07-30

Kalaris Therapeutics, Inc. statistics & valuation

Market cap$94.3M
P / B1.2×
Return on equity-55.1%
Return on capital-41.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-16182.40% 2019202020212022202320242025
Return on equity (%)
-19.80% -76.30% -75.10% -55.10% 2019202020212022202320242025
Shares outstanding
2.1M 61.9M 63.6M 93.1M 5.0M 1.4M 22.9M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-17.10% -18.80% -60.00% -60.90% -99.80% -1122.50% -35.70% 2019202020212022202320242025
Free cash flow margin (%)
-12420.60% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.74 -$2.20 -$42.09 -$51.77 -$2.85 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin——————-16182.4%
Net margin——————-14447.9%
FCF margin——————-12420.6%
Return on assets-35.7%-1122.5%-99.8%-60.9%-60.0%-18.8%-17.1%
Return on equity-55.1%71.6%423.0%-75.1%-76.3%-19.8%46.3%
Current ratio12.230.116.619.996.6929.3913.98

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.